Articles

If you would like your clinical trial or study (medication, genetics, therapies, etc.) included in our listings, send your information to This e-mail address is being protected from spambots. You need JavaScript enabled to view it. .

Alzheimer's and other Dementia

Vascular Dementia

Volunteers are needed to participate in a research study of an investigational drug that may manage the symptoms of vascular dementia. If someone close to you has suffered a stroke and has subsequent memory problems, he or she may be able to participate. 

Study volunteers must be:

• Between 50 and 85 years old
• In generally good health
• Able to have a caregiver participate in the study with them

Participants will receive at no charge:

• A full diagnostic evaluation, including an MRI
• Physical examinations
• Laboratory tests
• Study medication or placebo
• Patients who complete the study will be eligible to receive open label treatment with the new drug for up to one year 

For more information, call: 314-268-5880.  This study is being conducted by the Clinical Trials Unit, Department of Psychiatry, Saint Louis University School of Medicine.

Do you or someone you know have moderate to severe Alzheimer's disease?  If so, you or the person you know may be eligible to participate in a clinical research trial that could play an important role in providing a more effective treatment option in the treatment of Alzheimer's disease.

The clinical trial is now testing the safety and efficacy of an investigational drug called neramexane.  This trial will investigate whether neramexane can help improve patients' abilities to understand and retain information and perform daily tasks.

Participants must:

• Be at least 50 years old
• Have a knowledgeable and reliable caregiver who will accompany the patient to all clinic visits during the study period
• Not be on a cholinesterase inhibitor.  Participants currently on these medications, but wishing to seek an alternative to cholinesterase inhibitor therapy, may be eligible to participate.

Potential study participants should call:  314-268-5880 or 1-800-268-5880.

This study is being conducted by the Geriatric Psychiatry Division, Saint Louis University School of Medicine.

Have you or someone you know been diagnosed with Alzheimer's disease? You may be qualified to participate in a research study of an investigational medicine if you are 40 to 85 years old, and are experiencing any of these symptoms:

• Forgetfulness, especially about recent events
• Confusion or losing track of things
• Difficulty finding words
• Difficulty finding your way or performing familiar tasks
• Poor or impaired judgment
• Changes in mood, behavior, or personality
• Lack of interest in activities
• Needing help with simple daily tasks

Qualified participants will receive study-related medical evaluations and investigational medicine at no cost.  For more information, call 314-268-5385.

This study is being conducted by the Geriatric Psychiatry Division, Saint Louis University School of Medicine.

This is a Phase I, placebo-controlled study that consists of a single ascending-dose stage followed by a multi-dose, parallel-treatment stage.  This study will be conducted in approximately 50 adult patients between 50-85 years old who have mild to moderate Alzheimer’s disease. 

Inclusion Criteria:

• Diagnosis of probable Alzheimer’s disease
• Approved Alzheimer’s disease treatments must be stable for ≥ 3 months prior to screening
• Other prescription medications must be stable for ≥ 1 month prior to screening

Exclusion Criteria:

• Female patients with reproductive potential
• History of presence of any clinically significant CNS disease
• History of seizures, with the exception of childhood febrile seizures

Contact:
Dr. Angela Clemente      1-314-298-0001                 http://www.millenniumpa.com/

What is the Connection Study?  The Connection Study is a late-stage study of 525 patients to test the effects of Dimebon (a unique oral medication) in patients with Alzheimer’s disease.  The goal of the Connection Study is to determine if Dimebon safely improves cognition (thinking and awareness), memory, daily functioning, behavior, and the ability to care for oneself.  The Connection Study will also look at how Dimebon affects the lives of people caring for patients who are taking the medicine. 

Continuing treatment on Dimebon - All patients who complete the 6-month research study will be able to receive Dimebon at no financial cost until the drug is approved.

Inclusion Criteria:

• Adults ≥50 years of age
• Diagnosis of probable Alzheimer’s Disease
• MRI or CT (brain imaging) within 3 months of enrollment
• Have a reliable caregiver

*Contact for other eligibility criteria 

Exclusion Criteria:

• Any major medical illness, psychiatric disorder, or unstable medical condition within 6 months of screening that may interfere with the study
• History of clinically apparent stroke
• Other neurodegenerative diseases (Parkinson’s, Huntington’s, ALS, etc.)

*Contact for other restrictions

Contact:
Dr. Angela Clemente
1-314-298-0001
http://www.millenniumpa.com/

Anxiety Disorders

St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who are struggling with Generalized Anxiety Disorder. If you have taken medication for Generalized Anxiety Disorder in the past and are still struggling with symptoms of excessive worry, tension, trouble sleeping, or stress, you may qualify.  

Criteria for study qualification:

• Patients must be between the ages of 18 and 65
• Patients must be available to make weekly office visits for 10 weeks

Eligible patients will receive the following:

• Evaluation and care by a board-certified psychiatrist
• Routine laboratory draws and electrocardiograms
• Free medication
• Compensation for time and travel

If you are currently suffering from symptoms of generalized anxiety disorder and are interested in potentially trying a new medication to treat your anxiety symptoms, contact a Study Coordinator at Midwest Research Group at 636-946-8032 or visit www.MidwestResearchGroup.com.

Social Anxiety and “Focus on Relationships” study

The “Focus on Relationships” study is recruiting adults, age 18 or older, with social anxiety disorder and who are willing to bring a friend or romantic partner to a research study session. The friend/romantic partner will not be given any information about why you are participating in the study. This is not a medication clinical trial. Participants complete a psychological evaluation, computer tasks, interpersonal tasks and questionnaires. Participants who complete the study receive information about psychological diagnoses and tailored information that may help them find treatment. Qualifying participants and friend/romantic partner will receive monetary reimbursement.

For more information, contact the Anxiety and Psychotherapy Laboratory of Washington University in St. Louis at 314-935-8627 or visit www.anxlab.com and click on the “Focus on Relationships” button or visit www.FORstudySTL.com.

Mood Disorders

Adults with Major Depressive Disorder

Researchers are studying the efficacy, safety and tolerability of an antidepressant medication in treatment of adults 18-65 with major depressive disorder who currently are not taking psychiatric medication. The total duration of the study is 10 weeks. This is an outpatient study. 

Contact:
Dr. Angela  Clemente
314-298-0001
http://www.millenniumpa.com/

The Conte Center, Washington University School of Medicine, is conducting a study of schizophrenia.

The major goal of the Conte Center is to improve understanding of the underlying causes and mechanisms of schizophrenia, especially during its earliest phases. Volunteers of many kinds are needed to help the Conte Center achieve its goals.  If you have schizophrenia or are the brother or sister of someone with schizophrenia, you may be able to participate in research studies at Washington University School of Medicine. Participation will involve a no-cost MRI (Magnetic Resonance Imaging) scan, plus 8-10 hours for interviews and cognitive testing.  Every participant in the study will receive compensation for his/her time.

Principal Investigator: Deanna Barch, MD;   Sponsor: National Institute of Mental Health

For more information, call Juanita Bishop at 314-877-0756.

St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who have been diagnosed with schizophrenia and are interested in participating in an in-patient hospitalization trial followed by an outpatient extension study. 

Participants must meet the following criteria:

• Be between the ages of 18 and 75 years of age
• Be unhappy with current medications for schizophrenia
• Available to make office visits after the initial ten-day hospitalization

Eligible patients will receive the following:

• Evaluation and care by a board-certified psychiatrist
• Routine laboratory draws and electrocardiograms
• Free study medication
• Compensation for time and travel, including hospitalization

For more information and to see if you qualify please contact a Study Coordinator at Midwest Research Group at 636-946-8032.

Washington University School of Medicine in St. Louis has been awarded a federal grant from the National Institute of Mental Health (NIMH) to identify the genetic and environmental factors that may increase or decrease a person’s susceptibility of developing schizophrenia.

This study is a collaborative effort with eight other research programs in the United States and Australia. The goals of this research project are to improve our understanding of the causes of schizophrenia as well as the identification of the gene(s) that may lead to such a disorder.  Project results may lead to the development of methods of prevention and forms of new treatments aimed at curing the disease. 

Eligibility: 

• A participant must have schizophrenia or schizoaffective disorder.
• With the participant’s consent, his or her parents may be asked to participate.
• Each participant may be asked to complete two interviews; a confidential personal interview and family interview (approximately 2-4 hours to complete).  For each interview, the participant will be paid $25.00 for a total of $50.00
• Each participant may be asked to give a small blood sample for which an additional $25.00 will be paid.

Benefits:

• The participant will be contributing to the development of better treatments for schizophrenia.
• The participant will be contributing to the identification of gene(s) that may increase or decrease the susceptibility to schizophrenia. 

ALL information obtained from participants and their family members will be kept completely confidential.  

For more information, call: 

Individuals with a diagnosis of schizophrenia and no history of diabetes are being invited to participate in a study on the changes in blood sugar levels and weight that might occur during treatment with Depakote and antipsychotic medications.

Participation involves:

• A screening visit at Barnes-Jewish Hospital
• Three glucose tolerance tests at Barnes-Jewish Hospital
• Two overnight visits at Barnes-Jewish Hospital
• Willingness to try Depakote under the supervision of your doctor
• Regular check-ups with the research team

Participants will be compensated for their time and inconvenience. Transportation (cab) will be provided to and from all appointments. For more information, please contact Martha Hessler in the office of Dr. Daniel Haupt at 314-362-2423.

Individuals with a diagnosis of schizophrenia or schizoaffective disorder and no history of diabetes are being invited to participate in a study on the changes in blood sugar levels and weight that might occur during treatment with antipsychotic medications.

Participation involves:

• A screening visit at Barnes-Jewish Hospital
• Study-related tests (glucose tolerance tests, routine blood tests, MRI, and DXA scans) at Barnes-Jewish Hospital
• Willingness to try a different antipsychotic medication (Abilify) under the supervision of your doctor
• Regular check-ups with the research team

Participants will be compensated for their time and inconvenience. Transportation (cab) will be provided to and from all appointments. For more information, please contact Julie Schweiger in the office of Dr. John Newcomer at 314-362-3153.

Participation involves:

• A screening visit at Barnes-Jewish Hospital
• Three glucose tolerance tests at Barnes-Jewish Hospital
• Two overnight visits at Barnes-Jewish Hospital
• Willingness to try a different antipsychotic medication under the supervision of your doctor
• Regular check-ups with the research team

Participants will be compensated for their time and inconvenience. Transportation (cab) will be provided to and from all appointments. For more information, please contact Julie Schweiger in the office of Dr. John Newcomer at 314-362-3153.

The purpose of this study is to evaluate the safety, efficacy, and tolerability of an investigational medication relative to placebo in patients with acute exacerbation of schizophrenia.  The duration of the study is up to 56 days, which includes a safety follow-up period after the 6 weeks of double-blind treatment.

Inclusion criteria:

• Adults 18-60 years of age
• Diagnosis of Schizophrenia
• Within 12 months of starting the study, one psychotic episode which required hospitalization or change in medication
• Body mass index between 18 and 35

*Contact for other eligibility criteria

Exclusion criteria:

• Any major medical illness, psychiatric disorder, or unstable medical condition that may interfere with the study
• Active suicidal or homicidal intent or prior suicide or homicide attempt in the past 2 years
• History of cataracts

*Contact for other restrictions

Contact:
Dr. Angela Clemente
314-298-0001
http://www.millenniumpa.com/

Volunteers are needed for a research study of an investigational drug to see if it improves thinking skills like focusing, remembering and problem-solving in people with schizophrenia. Qualified participants must:

• Be 20 to 55 years of age
• Currently be taking prescription medication for schizophrenia
• Have had no psychiatric hospitalizations in the last four months

Participants will continue taking their antipsychotic medication during the course of the study while receiving the study drug.

All study-related medication and care is at no cost and compensation for time and travel is available. Health insurance is not needed. Studies are being conducted at the following locations:

For more information, call 314-546-4143 or visit  www.SRStudy.com

St. Charles Psychiatric Associates and Midwest Research Group are currently looking for patients who are struggling with symptoms of insomnia.

Eligibility criteria:

• Be at least 18 years old
• Have difficulty staying asleep during the night
• Complain of sleepiness during the day

Eligible patients will receive the following:

• Evaluation and care by a board-certified psychiatrist
• Routine laboratory draws and electrocardiograms
• Free study medication
• Compensation for time and travel

For more information or to see if you qualify, contact a Study Coordinator at Midwest Research Group at 636-946-8032 or visit www.MidwestResearchGroup.com.